Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy

Prenatal Diagnosis

Volumn 19, Issue 2, 1999, Pages 146-158

  Hsu, Jenn Jeih ^a   Spencer, Kevin ^b   Aitken, David A ^c   Crossley, Jenny ^c   Choi, Theresa ^b   Ozaki, Mikio ^d   Tazawa, Hiromitsu ^e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b HAROLD WOOD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Toagoesi Co Ltd   (Japan)

^e Sumitomo Metal Bio Science Inc   (Japan)

Author keywords

Down syndrome screening; Urine beta core; Urine free beta hCG; Urine total oestriol

Indexed keywords

BETA CORE FRAGMENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CREATININE; ESTRIOL; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DEVICE; DILUTION; DOWN SYNDROME; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATERNAL AGE; PRIORITY JOURNAL; SCREENING TEST; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; ESTRADIOL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 0033060669     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0223(199902)19:2<146::AID-PD502>3.0.CO;2-K     Document Type: Article

References (43)

1. Baviera, G. (1997). First trimester free beta hCG in maternal serum and urine as a Down syndrome marker. Clin. Chem., 43, S182.
2. Berry, E., Aitken, D.A., Crossley, J.A., Macri, J.N., Connor, J.M. (1997). Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimester, Br. J. Ohstet. Gynaecol., 104, 811-817.
3. Brambati, B., Lanzani, A., Tului, L. (1991). Ultrasound and biochemical assessment of first trimester pregnancy. In: Chapman, M., Grudzinskas, J.G., Chard, T. (Eds). The Embryo: Normal and Abnormal Development and Growth, New York: Springer-Verlag, 181-194.
4. Canick, J.A., Knight, G.J., Palomaki, G.E., Haddow, J.E., Cuckle, H.S., Wald, N.J. (1988). Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome, Br. J. Obstet. Gynaecol., 95, 330-333.
5. Canick, J.A., Kellner, L.H., Saller, D.N., Palomaki, G.E., Walker, R.P., Osanthanondh, R. (1995). Second trimester levels of maternal urinary gonadotropin peptide in Down syndrome pregnancy, Prenat. Diagn., 15, 739-744.
6. Canick, J.A., Kellner, L.H., Saller, D.N., Palomaki, G.E., Tumber, M.B., Messerlian, G.L., Walker, R.P., Osanthanondh, R. (1996). A second level evaluation of maternal urinary gonadotropin peptide as a marker for second trimester Down syndrome screening. Recent Advances in Prenatal Diagnosis for Aneuploidy, Abstract 28.
7. Cole, L.A. (1995). Down's syndrome screening using urine beta core fragment test: choice of immunoassay, Prenat. Diagn., 15, 679-682.
8. Cole, L.A., Jacobs, M., Isozaki, T., Palomaki, G.E., Bahado-Singh, R.O., Mahoney, M.J. (1997a). Screening for Down syndrome using urine hCG free beta subunit in the second trimester of pregnancy, Prenat. Diagn., 17, 1107-1111.
9. Cole, L.A., Acuna, E., Isozaki, T., Palomaki, G.E., Bahado-Singh, R.O., Mahoney, M.J. (1997b). Combining beta core fragment and total oestriol measurements to test for Down syndrome pregnancies, Prenat. Diagn., 17, 1125-1133.
10. Cole, L.A., Kellner, L.H., Isozaki, T., Palomaki, G.E., Iles, R.K., Walker, R.P., Ozaki, M., Canick, J.A. (1997c). Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies, Prenat. Diagn., 17, 607-614.
11. Cuckle, H. (1997). Fetal nuchal translucency test for Down's syndrome. Lancet. 350, 1629-1630.
12. Cuckle, H.S., Iles, R.K., Chard, T. (1994). Urinary beta core human chorionic gonadotrophin: a new approach to Down's syndrome screening, Prenat. Diagn., 14, 953-958.
13. Cuckle, H.S., Iles, R.K., Sehmi, I.K., Oakey, R.E., Davies, S., Ind. T. (1995). Urinary multiple marker screening for Down's syndrome, Prenat. Diagn., 15, 745-751.
14. Cuckle, H.S., Canick, J.A., Kellner, L.H., VanLith, J.M.M., White, I., Helbig, B.R., Rose, N.C., Sehmi, I.K., Jones, R. (1996). Urine beta core hCG screening in the first trimester. Prenat. Diagn., 16, 1057-1059.
15. Grudzinskas, J.G., Ward, R.H.T. (eds) (1997). Screening for Down syndrome in the First Trimester, London: RCOG Press.
16. Hallahan, T.W., Krantz, D.A., Tului, L., Alberti, E., Buchanan, P.D., Orlandi, F., Klein, V., Larsen, J.W., Macri, J.N. (1998). Comparison of urinary free beta hCG and beta core hCG in prenatal screening for chromosomal abnormalities, Prenat. Diagn., 18, 893-900.
17. Hayashi, M., Kozu, H. (1995). Maternal urinary beta core fragment of hCG/creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. Prenat. Diagn., 15, 11-16.
18. Hayashi, M., Kozu, H., Takei, H. (1996). Maternal urinary free beta subunit of human chorionic gonadotrophin: creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy, Br. J. Obstet. Gynaecol. 103, 577-580.
19. Isozaki, T., Palomaki, G.E., Bahado-Singh, R.O., Cole, L.A. (1997). Screening for Down syndrome pregnancy using beta core fragment: prospective study, Prenat. Diagn., 17, 407-413.
20. Jorgensen, P.I., Trolle, D. (1972). Low urinary oestriol excretion during pregnancy in women giving birth to infants with Down's syndrome. Lancet, ii, 782-784.
21. Kellner, L.H., Canick, J.A., Palomaki, G.E., Neveux, L.M., Saller, D.N., Walker, R.P., Osathanondh, R., Bombard, A.T. (1997). Levels of urinary beta core fragment, total oestriol and the ratio of the two in second trimester screening for Down syndrome, Prenat. Diagn., 17, 1135-1141.
22. Kornman, L.H., Morssink, L.P., Wortelboer, M.J.M.. Beekhuis, J.R., de Wolf, B.T.H.M., Pratt, J.J., Mantingh, A. (1997). Maternal urinary beta core hCG in chromosomally abnormal pregnancies in the first trimester, Prenat. Diagn., 17, 135-139.
23. Krantz, D.A., Larsen, J.W., Buchanan, P.D., Macri, J.N. (1996). First trimester Down syndrome screening: free beta human chorionic gonadotropin and pregnancy-associated plasma protein A, Am. J. Obstet. Gynecol., 174, 612-616.
24. Lam, Y.H., Tang, M.H.Y., Tang, L.C.H., Lee, C.P., Ho, P.K.H. (1997). Second trimester maternal urinary gonadotrophin peptide screening for fetal Down syndrome in Asian women, Prenat. Diagn., 17, 1101-1106.
25. Macintosh, M.C.M., Nicolaides, K.H., Noble, P., Chard, T., Gunn, L., Iles, R. (1997). Urinary beta core hCG: screening for aneuploidies in early pregnancy (11-14 weeks' gestation). Prenat. Diagn., 17, 401-405.
26. Macri, J.N., Spencer, K. (1996). Towards the optimal protocol for Down's syndrome screening. Am. J. Obstet. Gynecol., 174, 1668-1669.
27. Macri, J.N., Spencer, K., Anderson, R.W., Cooke, E.J. (1993). Free beta chorionic gonadotropin: a cross reactivity study of two immunometric assays used in prenatal maternal serum screening for Down's syndrome. Ann. Clin. Biochem., 30, 94-98.
28. Macri, J.N., Spencer, K., Carver, K., Buchanan, P.D., Say, B., Carpenter, N.J., Muller, F., Boue, A. (1994). Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome. Prenat. Diagn., 14, 97-103.
29. Nicolaides, K.H., Snijders, R.M., Noble, P.L., Brizot, M., Sebire, N.J. (1997). First trimester ultrasound screening for chromosomal defects. In: Grudzinskas, J.G., Ward, R.H.T. (Eds). Screening for Down Syndrome in the First Trimester, London: RCOG Press, 197-212.
30. Office of Population Censuses and Surveys (1991-1994). Birth statistics, Series FMI, Nos 18-21: London: HMSO.
31. Reynolds, T., Penney, M. (1990). The mathematical basis of multivariate risk analysis; with special reference to screening for Down syndrome associated pregnancy, Ann. Clin. Biochem., 27, 452-458.
32. Royston, P., Thompson, S.G. (1992). Model based screening by risk with application to Down's syndrome. Stat. Med., 11, 257-268.
33. Spencer, K. (1986). Analytical reviews in clinical biochemistry: the estimation of creatinine, Ann. Clin. Biochem., 23, 1-25.
34. Spencer, K. (1994). Despistage de la trisomie 21 a l'aide de la beta hCG libre: notre experience sur trois ans, Med. Foetale Echographie Gynecol., 20, 67-69.
35. Spencer, K. (1997a). Biochemical screening for neural tube defects and chromosomal abnormalities. The Diplomate, 4, 38-43.
36. Spencer, K. (1997b). hCG and its subunits in first trimester Down syndrome screening. In: Grudzinskas, J.G., Ward, R.H.T. (Eds). Screening for Down Syndrome in the First Trimester, London: RCOG Press, 117-131.
37. Spencer, K., Coombes, E.J., Mallard, A.S., Milford-Ward, A. (1992). Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers, Ann. Clin. Biochem., 29, 506-518.
38. Spencer, K., Aitken, D.A., Crossley, J.A., McCaw, G., Berry, E., Anderson, R.V., Connos, J.M. (1994). First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein - A, Ann. Clin. Biochem., 34, 447-454.
39. Spencer, K., Aitken, D.A., Macri, J.N., Buchanan, P.D. (1996). Urine free beta hCG and beta core in pregnancies affected by Down's syndrome, Prenat. Diagn., 16, 605-613.
40. Spencer, K., Noble, P., Snijders, R.J.M., Nicolaides, K.H. (1997a). First trimester urine free beta hCG, beta core and total oestriol in pregnancies affected by Down's syndrome: implications for first trimester screening with nuchal translucency and serum free beta hCG. Prenat. Diagn., 17, 525-538.
41. Spencer, K., Muller, F., Aitken, D.A. (1997b). Biochemical markers of trisomy 21 in amniotic fluid. Prenat. Diagn., 17, 31-37.
42. Spencer, K., Souter, V., Tul, N., Snijders, R., Nicolaides, K.H. (1999). A screening program for Trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta hCG and PAPP-A, Ultrasound Obstet. Gynecol., in press.
43. Wald, N.J., George, L., Smith, D., Densem, J.W., Pettersson, K. (1996), Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br. J. Obstet. Gynaecol., 103, 407-412.